Streetbeat News

Products Services

JNJ

Johnson & Johnson announced that its drug TREMFYA® has shown significant results in treating Crohn's disease and ulcerative colitis, achieving high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients. TREMFYA® is FDA-approved for ulcerative colitis and under review for Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:08 pm

CHPT

ChargePoint has introduced a new home installation program for its ChargePoint Home Flex in the U.S., providing a streamlined and cost-effective solution for residential EV charging.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:08 pm

WAT

Waters Corporation has launched new bioseparation tools, including LC-MS grade reagents, enzymes, and software, to enhance RNA-based vaccine and therapy development. These tools improve RNA analysis, aiding in the development of mRNA vaccines and genetic disorder drugs.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:06 pm

IBIO

iBio and AstralBio have identified a promising molecule for treating muscle wasting and obesity. This molecule is designed for subcutaneous administration and may have an extended half-life. The companies plan to advance it into non-cGMO in vivo studies.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:06 pm

VSAT

Viasat, Inc. (NASDAQ:VSAT) has begun delivering its ViaSat-3 F1 satellite service to the U.S. Marine Corps, marking the first government use of the ViaSat-3 network. This service supports military communications and reconnaissance operations.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:05 pm

MOVE

Movano Health has provided an update on the FDA review of its EvieMED Ring, stating that it has received additional questions in the final phase of its 510(k) application. The company remains optimistic about obtaining clearance after addressing initial wellness features.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:03 pm

RNG

RingCentral Inc. has received a PAN-India license to offer fully compliant UCaaS and CCaaS solutions, enabling seamless communication for multinational organizations in India. This positions RingCentral as a leader in AI-powered business communications.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:03 pm

NAAS

NaaS Technology is focusing on its interconnectivity charging business, leveraging AI and partnerships to boost ecosystem development in China's expanding EV market.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:03 pm

AKBA

Akebia Therapeutics announced that its drug Vafseo has been approved for the Transitional Drug Add-On Payment Adjustment by CMS, starting January 1, 2025. This will provide two years of additional reimbursement for dialysis organizations.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:02 pm